A vitamin found in nearly every multivitamin aisle just showed real promise against a disease that affects millions of American skin.
Story Snapshot
- Scientists in China found that pantethine, a form of vitamin B5, calmed the immune cells that drive psoriasis flare-ups.
- A small 12-week human trial paired pantethine with standard topical treatment and tracked results in 24 patients.
- The study, published in the Journal of Experimental Medicine, also showed the supplement blocked psoriasis-like disease in mice.
- Researchers tied the effect to a newly described metabolic pathway involving an enzyme called vanin.
What The New Research Actually Found
Researchers discovered that pantethine interferes with dendritic cells, the immune messengers that tell the body to attack its own skin in psoriasis. The team published their work October 27 in the Journal of Experimental Medicine, describing a link between cholesterol-related metabolism and immune activation that had not been mapped out before. That connection matters because psoriasis has long been treated as a skin problem first, not a metabolic one.
The lab work centered on something called the vanin-pantetheine axis. Vanin is an enzyme that breaks down a related compound in the body. When researchers blocked that enzyme or added pantethine directly, dendritic cells from patients with autoimmune disorders calmed down, and disease progression slowed in experimental models. That gave the team enough confidence to test the compound in actual psoriasis patients.
How The Human Trial Was Set Up
Scientists enrolled 24 patients with plaque psoriasis and split them into two groups after applying strict exclusion criteria. One group received a standard topical treatment alone. The other received that same treatment plus daily pantethine supplements. After 12 weeks, researchers compared how much each group’s skin symptoms had improved, looking for signs that the supplement added benefit beyond standard care.
Patients who took pantethine alongside their topical treatment showed greater improvement than those using the topical alone, according to the published findings. Mouse studies run in parallel showed pantethine actually prevented psoriasis-like skin disease from developing in the first place, not just treating it after symptoms appeared. That two-pronged result, prevention in mice and improvement in humans, is what pushed the study into major headlines.
Why Vitamin B5 Keeps Surfacing In Autoimmune Research
Pantethine is not some exotic lab chemical. It is a derivative of vitamin B5, sold widely as an over-the-counter supplement, often marketed for cholesterol support long before anyone connected it to psoriasis. That familiarity is part of why this finding grabbed attention. A compound already sitting on store shelves showed it could quiet the exact immune cells responsible for one of the most stubborn skin conditions doctors treat.
A separate laboratory study using a 3D human psoriatic skin model found pantethine helped restore normal skin cell behavior and affected proteins tied to how skin cells manage internal transport systems. That adds a second, independent layer of evidence pointing toward the same conclusion from a different angle, strengthening the case that something real is happening at the cellular level.
What This Means For Patients And Future Research
Psoriasis affects millions of Americans, and many rely on topical steroids or expensive biologic injections that carry their own risks and costs. A cheap, widely available supplement that boosts standard treatment results would be a welcome option for families tired of paying high prices for relief. It is worth remembering this involved just 24 patients over 12 weeks, so larger trials will need to confirm these results before doctors recommend it broadly.
Dietary supplements in the United States are not reviewed by the Food and Drug Administration for effectiveness before they hit shelves, and companies cannot legally claim a supplement treats or cures a disease without separate approval. That regulatory gap means patients curious about pantethine should talk to their own dermatologist rather than assume supplement labels reflect this new research. The science is promising, but the next step belongs to bigger clinical trials, not marketing copy.
For now, the finding stands as a genuine scientific discovery worth watching closely. Researchers mapped a new metabolic pathway, tested it in cells, confirmed it in mice, and then validated it in real patients. That is the kind of layered evidence that earns attention in medicine, even while everyone involved acknowledges more work lies ahead before pantethine becomes a standard part of psoriasis care.
Sources:
sciencedaily.com, pubmed.ncbi.nlm.nih.gov, rupress.org, weny.com, m3globalresearch.com
